Free tool
FAERS Monitor: Tiglutik Kit
Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209080 or its brand name (Tiglutik Kit, Riluzole). Reports on generic versions are filed under their own applications.
Reports
2,216
Serious
1,375
62% of reports
Hospitalization
526
Death reported
521
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death319
- nausea155
- diarrhoea138
- drug ineffective100
- disease progression96
- amyotrophic lateral sclerosis92
- fatigue92
- dyspnoea89
- asthenia82
- dizziness79
- muscular weakness71
- abdominal discomfort68
- off label use64
- headache59
- pneumonia52
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 15 |
| 2006 | 7 |
| 2007 | 10 |
| 2008 | 9 |
| 2009 | 6 |
| 2010 | 13 |
| 2011 | 11 |
| 2012 | 15 |
| 2013 | 27 |
| 2014 | 21 |
| 2015 | 35 |
| 2016 | 39 |
| 2017 | 98 |
| 2018 | 134 |
| 2019 | 207 |
| 2020 | 264 |
| 2021 | 194 |
| 2022 | 179 |
| 2023 | 310 |
| 2024 | 239 |
| 2025 | 209 |
| 2026 | 168 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,943 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| amyotrophic lateral sclerosisSignal | 92 | 423.4 | 345.1 | 36,719 |
| disease progressionSignal | 96 | 7.7 | 6.3 | 556 |
| muscular weaknessSignal | 71 | 5.9 | 4.7 | 288 |
| abdominal discomfortSignal | 68 | 3.8 | 3.0 | 142 |
| deathSignal | 319 | 3.5 | 3.2 | 596 |
| astheniaSignal | 82 | 2.1 | 1.7 | 45 |
| diarrhoeaSignal | 138 | 2.0 | 1.7 | 73 |
| nausea | 155 | 1.9 | 1.6 | 63 |
| pneumonia | 52 | 1.5 | 1.2 | 9 |
| dizziness | 79 | 1.5 | 1.2 | 13 |
| dyspnoea | 89 | 1.5 | 1.2 | 14 |
| fatigue | 92 | 1.1 | 0.9 | 1 |
| headache | 59 | 0.9 | 0.7 | 1 |
| drug ineffective | 100 | 0.7 | 0.6 | 11 |
| off label use | 64 | 0.7 | 0.5 | 9 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.